87.69 USD
+2.29 (+2.68%)
87.69 USD
0 (0%)
Overall PTGX gets a fundamental rating of 5 out of 10. We evaluated PTGX against 533 industry peers in the Biotechnology industry. PTGX has an excellent financial health rating, but there are some minor concerns on its profitability. PTGX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year PTGX was profitable.
PTGX had a positive operating cash flow in the past year.
In the past 5 years PTGX reported 4 times negative net income.
PTGX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PTGX has a better Return On Assets (6.54%) than 92.50% of its industry peers.
PTGX has a Return On Equity of 7.11%. This is amongst the best in the industry. PTGX outperforms 92.31% of its industry peers.
With an excellent Return On Invested Capital value of 2.29%, PTGX belongs to the best of the industry, outperforming 90.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| ROIC | 2.29% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 21.94%, PTGX belongs to the best of the industry, outperforming 94.56% of the companies in the same industry.
PTGX has a better Operating Margin (9.09%) than 91.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.09% | ||
| PM (TTM) | 21.94% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PTGX is destroying value.
PTGX has more shares outstanding than it did 1 year ago.
PTGX has more shares outstanding than it did 5 years ago.
PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PTGX has an Altman-Z score of 57.41. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 57.41, PTGX belongs to the best of the industry, outperforming 97.37% of the companies in the same industry.
PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 57.41 |
ROIC/WACC0.26
WACC8.7%
2.3 Liquidity
PTGX has a Current Ratio of 13.05. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.05, PTGX belongs to the best of the industry, outperforming 88.37% of the companies in the same industry.
A Quick Ratio of 13.05 indicates that PTGX has no problem at all paying its short term obligations.
PTGX's Quick ratio of 13.05 is amongst the best of the industry. PTGX outperforms 88.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.05 | ||
| Quick Ratio | 13.05 |
3. Growth
3.1 Past
The earnings per share for PTGX have decreased strongly by -76.69% in the last year.
Looking at the last year, PTGX shows a very negative growth in Revenue. The Revenue has decreased by -35.39% in the last year.
PTGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 352.10% yearly.
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
3.2 Future
The Earnings Per Share is expected to decrease by -1.37% on average over the next years.
Based on estimates for the next years, PTGX will show a small growth in Revenue. The Revenue will grow by 7.84% on average per year.
EPS Next Y-148.12%
EPS Next 2Y-51.05%
EPS Next 3Y-31.32%
EPS Next 5Y-1.37%
Revenue Next Year-80.16%
Revenue Next 2Y-30.96%
Revenue Next 3Y-15.85%
Revenue Next 5Y7.84%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PTGX is valuated quite expensively with a Price/Earnings ratio of 141.44.
88.93% of the companies in the same industry are more expensive than PTGX, based on the Price/Earnings ratio.
PTGX is valuated expensively when we compare the Price/Earnings ratio to 25.47, which is the current average of the S&P500 Index.
PTGX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 141.44 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PTGX is valued cheaply inside the industry as 89.49% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PTGX indicates a rather cheap valuation: PTGX is cheaper than 91.56% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 86.05 | ||
| EV/EBITDA | 210.32 |
4.3 Compensation for Growth
PTGX's earnings are expected to decrease with -31.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-51.05%
EPS Next 3Y-31.32%
5. Dividend
5.1 Amount
No dividends for PTGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
87.69
+2.29 (+2.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners114.41%
Inst Owner Change-0.12%
Ins Owners1.02%
Ins Owner Change-1.64%
Market Cap5.48B
Revenue(TTM)209.22M
Net Income(TTM)45.91M
Analysts85
Price Target91.65 (4.52%)
Short Float %9.04%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.83%
Min EPS beat(2)4.88%
Max EPS beat(2)6.78%
EPS beat(4)4
Avg EPS beat(4)133.89%
Min EPS beat(4)4.88%
Max EPS beat(4)504.52%
EPS beat(8)8
Avg EPS beat(8)266.75%
EPS beat(12)10
Avg EPS beat(12)179.39%
EPS beat(16)14
Avg EPS beat(16)139.25%
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-20.11%
Max Revenue beat(2)27.04%
Revenue beat(4)2
Avg Revenue beat(4)57.59%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)232.24%
Revenue beat(8)5
Avg Revenue beat(8)57.26%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)28.2%
PT rev (3m)30.92%
EPS NQ rev (1m)7.44%
EPS NQ rev (3m)6.38%
EPS NY rev (1m)0.5%
EPS NY rev (3m)-1.96%
Revenue NQ rev (1m)-1.63%
Revenue NQ rev (3m)40.92%
Revenue NY rev (1m)1.57%
Revenue NY rev (3m)-21.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 141.44 | ||
| Fwd PE | N/A | ||
| P/S | 26.2 | ||
| P/FCF | 86.05 | ||
| P/OCF | 83.74 | ||
| P/B | 8.49 | ||
| P/tB | 8.49 | ||
| EV/EBITDA | 210.32 |
EPS(TTM)0.62
EY0.71%
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)1.02
FCFY1.16%
OCF(TTM)1.05
OCFY1.19%
SpS3.35
BVpS10.32
TBVpS10.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| ROCE | 2.89% | ||
| ROIC | 2.29% | ||
| ROICexc | 18.62% | ||
| ROICexgc | 18.62% | ||
| OM | 9.09% | ||
| PM (TTM) | 21.94% | ||
| GM | N/A | ||
| FCFM | 30.45% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 121.94% | ||
| Cap/Sales | 0.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 320.17% | ||
| Profit Quality | 138.78% | ||
| Current Ratio | 13.05 | ||
| Quick Ratio | 13.05 | ||
| Altman-Z | 57.41 |
F-Score5
WACC8.7%
ROIC/WACC0.26
Cap/Depr(3y)47.62%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
EPS Next Y-148.12%
EPS Next 2Y-51.05%
EPS Next 3Y-31.32%
EPS Next 5Y-1.37%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
Revenue Next Year-80.16%
Revenue Next 2Y-30.96%
Revenue Next 3Y-15.85%
Revenue Next 5Y7.84%
EBIT growth 1Y-87.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-200.27%
EBIT Next 3Y-30.78%
EBIT Next 5YN/A
FCF growth 1Y153.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y155.09%
OCF growth 3YN/A
OCF growth 5YN/A
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you provide the ChartMill fundamental rating for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to PTGX.
Can you provide the valuation status for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a valuation rating of 3 / 10 to PROTAGONIST THERAPEUTICS INC (PTGX). This can be considered as Overvalued.
How profitable is PROTAGONIST THERAPEUTICS INC (PTGX) stock?
PROTAGONIST THERAPEUTICS INC (PTGX) has a profitability rating of 4 / 10.
Can you provide the financial health for PTGX stock?
The financial health rating of PROTAGONIST THERAPEUTICS INC (PTGX) is 8 / 10.
Can you provide the expected EPS growth for PTGX stock?
The Earnings per Share (EPS) of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -148.12% in the next year.